Asia On The Move: CFDA Deputy Head Takes On Key Liaison Role
This article was originally published in PharmAsia News
Wu Zhen is the latest China FDA senior official to serve as a liaison between the agency and the National Health and Family Planning Commission, as the regulatory reform enters a cross-agency collaboration stage.
You may also be interested in...
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.